BRCA1 and neoplasm: Concurrent therapy with PARPi and WEE1i at doses mimicking those used in combination in clinical trials60 was shown to trigger proinflammatory, anti-tumour immune responses in BRCA1/2 wild-type AT3OVA and AT3 tumours.